managing-adverse-drug-reactions

name	managing-adverse-drug-reactions
description	Classifies and documents adverse drug reactions with causality assessment (Naranjo) and reporting. Use when evaluating ADRs, assessing drug causality, or reporting adverse events.
tags	["management","pharmacy"]
metadata	{"author":"casemark","practice_areas":["Clinical Pharmacy","Pharmacy"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing Adverse Drug Reactions

Classifies and documents adverse drug reactions with causality assessment using the Naranjo algorithm and structured reporting through FDA MedWatch and institutional systems.

Why This Skill Exists

Adverse drug reactions (ADRs) are the fourth leading cause of death in the United States, causing an estimated 100,000 deaths and 2.2 million serious reactions annually. ADRs account for approximately 6.5% of all hospital admissions and prolong hospital stays by an average of 2 days. Despite FDA post-marketing surveillance requirements, fewer than 10% of serious ADRs are reported to MedWatch, creating a significant pharmacovigilance gap.

Pharmacists are uniquely positioned to detect, assess, manage, and report ADRs. Causality assessment using validated tools—the Naranjo Adverse Drug Reaction Probability Scale being the most widely used—is essential to distinguish true drug-caused reactions from coincidental events, disease progression, or drug interactions. The WHO-UMC causality system and the FDA Adverse Event Reporting System (FAERS) depend on structured reports from healthcare professionals. Institutions are required by the Joint Commission to have ADR reporting and monitoring programs, and the pharmacist typically manages this process.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the suspected adverse reaction (description, onset, severity)? (Default: document in detail)
2. What is the suspected causative drug (name, dose, route, start date)? (Default: identify)
3. What is the temporal relationship between drug exposure and reaction onset? (Default: establish timeline)
4. Are there alternative explanations (disease progression, other drugs, infection)? (Default: evaluate differentials)
5. Was the drug dechallenge performed (stopped/reduced)? If so, did the reaction improve? (Default: document)
6. Was rechallenge performed (restarted)? If so, did the reaction recur? (Default: document if applicable)
7. What is the patient's allergy and ADR history? (Default: review chart)
8. What is the reaction severity (mild, moderate, severe, life-threatening, fatal)? (Default: classify per NCC MERP or CTCAE)

Documents to Request

• Complete medication list with start dates and dose changes
• Clinical timeline of symptoms (onset, progression, resolution)
• Relevant lab values (CBC, CMP, LFTs, drug levels, specific biomarkers)
• Allergy and ADR history from patient chart
• Physician documentation of the reaction
• Any prior exposure to the suspected drug or drug class
• Previous ADR reports for this patient
• FDA drug label (adverse reactions section) for the suspected agent

---

Step 1: Classify the Adverse Drug Reaction

By mechanism (Rawlins-Thompson classification):

Type	Name	Characteristics	Examples
A	Augmented	Dose-dependent, predictable, related to pharmacologic action	Hypoglycemia from insulin, bleeding from warfarin, bradycardia from beta-blockers
B	Bizarre	Dose-independent, unpredictable, immunologic or idiosyncratic	Anaphylaxis from penicillin, Stevens-Johnson syndrome, malignant hyperthermia
C	Chronic	Dose and time-dependent, cumulative	Osteoporosis from corticosteroids, nephrotoxicity from lithium
D	Delayed	Time-dependent, appear after long latency	Carcinogenesis, teratogenicity (thalidomide)
E	End of use	Withdrawal reactions	Rebound hypertension from clonidine, benzodiazepine withdrawal seizures
F	Failure	Unexpected therapeutic failure, often dose-related	Oral contraceptive failure with enzyme inducers

By severity (CTCAE v5.0 grading):

• Grade 1: Mild; asymptomatic or mild symptoms
• Grade 2: Moderate; minimal local or noninvasive intervention indicated
• Grade 3: Severe; significant but not immediately life-threatening; hospitalization indicated
• Grade 4: Life-threatening; urgent intervention indicated
• Grade 5: Death related to adverse event

---

Step 2: Apply the Naranjo Causality Assessment

Score each question and sum for total probability:

#	Question	Yes	No	Unknown
1	Are there previous conclusive reports on this reaction?	+1	0	0
2	Did the adverse event appear after the suspected drug was administered?	+2	-1	0
3	Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?	+1	0	0
4	Did the adverse reaction reappear when the drug was readministered?	+2	-1	0
5	Are there alternative causes (other than the drug) that could on their own have caused the reaction?	-1	+2	0
6	Did the reaction reappear when a placebo was given?	-1	+1	0
7	Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?	+1	0	0
8	Was the reaction more severe when the dose was increased, or less severe when the dose was decreased?	+1	0	0
9	Did the patient have a similar reaction to the same or similar drugs in any previous exposure?	+1	0	0
10	Was the adverse event confirmed by any objective evidence?	+1	0	0

Scoring interpretation:

• ≥9: Definite ADR
• 5-8: Probable ADR
• 1-4: Possible ADR
• ≤0: Doubtful ADR

---

Step 3: Manage the Adverse Drug Reaction

Immediate management based on severity:

Severity	Actions
Mild (Grade 1)	Continue drug if benefit > risk; monitor; counsel patient
Moderate (Grade 2)	Consider dose reduction, temporary hold, or symptomatic treatment
Severe (Grade 3)	Discontinue suspected agent; provide supportive care; consider alternative therapy
Life-threatening (Grade 4)	Discontinue immediately; emergency supportive care; ICU level monitoring
Fatal (Grade 5)	Post-event analysis; report to FDA and institution

Drug-specific reversal and management:

• Anaphylaxis: Epinephrine 0.3-0.5 mg IM (EpiPen), IV fluids, diphenhydramine, corticosteroids, airway management
• Warfarin-related major bleeding: 4-factor PCC + vitamin K 10 mg IV
• Serotonin syndrome: Discontinue all serotonergic agents; cyproheptadine 12 mg initial then 4 mg q2h; supportive care
• Neuroleptic malignant syndrome: Discontinue antipsychotic; dantrolene, bromocriptine; ICU support
• Drug-induced QT prolongation/TdP: Discontinue offending agent; IV magnesium 2 g; temporary pacing if needed

---

Step 4: Document and Report

Internal documentation (in medical record):

1. Suspected drug, dose, route, dates of administration
2. Description of the adverse reaction with onset timing
3. Naranjo score with individual question responses
4. Causality classification (definite, probable, possible, doubtful)
5. Severity grade (CTCAE or NCC MERP)
6. Management actions taken
7. Outcome (resolved, resolving, ongoing, fatal)
8. Allergy/ADR list updated with reaction type (NOT just "allergy")

External reporting:

• FDA MedWatch (Form 3500/3500A): Required for serious ADRs (death, life-threatening, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent harm)
• ISMP Medication Error Reporting Program (MERP): For medication errors that caused or could have caused ADRs
• Institutional ADR reporting system: Per policy, all significant ADRs
• Manufacturer reporting: Required within 15 days for serious unexpected reactions

---

Step 5: Prevent Recurrence

1. Update allergy/ADR list in ALL systems (EHR, pharmacy profile, patient card) with specific reaction type
2. Differentiate allergy (immune-mediated) from intolerance (non-immune side effect) and document clearly
3. Identify cross-reactivity risks (e.g., penicillin allergy → cephalosporin cross-reactivity ~2%, carbapenem <1%)
4. Recommend alternatives: specify drugs within the class that are safe to use and those that are cross-reactive
5. Communicate to prescriber, nursing, and patient/caregiver
6. If the ADR represents a drug class effect, flag the entire class

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Was the Naranjo scale completed with all 10 questions scored?
2. Were alternative causes systematically evaluated before attributing causality?
3. Was dechallenge/rechallenge information documented?
4. Has the allergy/ADR list been updated with specific reaction type (not just "allergy")?
5. Was the ADR reported to FDA MedWatch if it meets serious criteria?

---

Quality Audit

• Adverse reaction described with specific symptoms, onset, and timeline
• Suspected drug identified with dose, route, and administration dates
• Naranjo Adverse Drug Reaction Probability Scale completed with total score
• Causality classified (definite, probable, possible, doubtful)
• Severity graded using CTCAE or NCC MERP classification
• Alternative causes evaluated (disease, other drugs, interactions)
• Dechallenge information documented (reaction improvement on drug removal)
• Rechallenge information documented if applicable (recurrence on re-exposure)
• Management actions specified (discontinuation, dose change, antidote, supportive care)
• Allergy/ADR list updated in EHR with reaction type (immune vs. non-immune)
• Cross-reactivity assessed and safe alternatives documented
• FDA MedWatch report filed for serious ADRs
• Institutional ADR reporting system notification completed
• Patient and prescriber notified of ADR assessment and recommendations

---

Guidelines

• Distinguish allergy from intolerance from side effect when documenting ADRs; imprecise labels cause future therapeutic avoidance of safe drugs
• The Naranjo score is a structured guide, not a definitive diagnostic; clinical judgment remains essential
• Always evaluate the entire medication list for potential causative agents; the most recently started drug is suspect but not always the cause
• Report to FDA MedWatch even when causality is "possible"—post-marketing surveillance depends on aggregate reporting
• Rechallenge is generally NOT recommended unless the drug is essential and no alternative exists; it requires informed consent and monitoring
• Cross-reactivity between penicillins and cephalosporins is lower than historically cited (~2%, not 10%); do not reflexively avoid cephalosporins in penicillin-allergic patients
• Penicillin skin testing should be considered to de-label patients with unverified penicillin allergy
• Time-stamp all ADR assessments; causality may change as new information becomes available